Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1899 Target Snapshot

5-hydroxytryptamine receptor 3A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,328Compounds
509Assays
22Approved Drugs
1,760.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

5-hydroxytryptamine receptor 3A shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P46098. Start with cancer, then reuse UniProt P46098 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P46098 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 7 linked drugs
Open source guide
Disease program
cancer

5-hydroxytryptamine receptor 3A shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 7 linked drugs remain visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include DOLASETRON MESYLATE, GRANISETRON, GRANISETRON HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 7 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 3A as ChEMBL target CHEMBL1899, mapped to UniProt P46098. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 3A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1899
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P46098
5-hydroxytryptamine receptor 3A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 3A is the right protein anchor across sources, using UniProt P46098 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 7 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name5-hydroxytryptamine receptor 3A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP46098
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 3A
UniProt AccessionP46098
Component TypeProtein
Sequence Length478 aa

5-hydroxytryptamine receptor 3A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 3A, mapped to UniProt P46098. Sequence length is 478 aa.

Mapped IDP46098
Review name5-hydroxytryptamine receptor 3A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

5-hydroxytryptamine receptor 3A shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
7 linked drugs · 7 direct · 7 efficacy
Linked drugDOLASETRON MESYLATE
Linked drugGRANISETRON
Linked drugGRANISETRON HYDROCHLORIDE
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Approved-linked Approved
Nausea and vomiting
7 linked drugs · 7 direct · 7 efficacy
Linked drugDOLASETRON MESYLATE
Linked drugGRANISETRON
Linked drugGRANISETRON HYDROCHLORIDE
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Approved-linked Approved
post operative nausea and vomiting
6 linked drugs · 6 direct · 6 efficacy
Linked drugDOLASETRON MESYLATE
Linked drugGRANISETRON
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Linked drugONDANSETRON
Approved-linked Approved
Chemotherapy-induced nausea and vomiting
5 linked drugs · 5 direct · 5 efficacy
Linked drugGRANISETRON
Linked drugGRANISETRON HYDROCHLORIDE
Linked drugONDANSETRON
Linked drugONDANSETRON HYDROCHLORIDE
Approved-linked Approved
Nausea
5 linked drugs · 5 direct · 5 efficacy
Linked drugGRANISETRON
Linked drugGRANISETRON HYDROCHLORIDE
Linked drugONDANSETRON
Linked drugONDANSETRON HYDROCHLORIDE
Approved-linked Approved
Vomiting
5 linked drugs · 5 direct · 5 efficacy
Linked drugGRANISETRON
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Linked drugONDANSETRON
Linked drugONDANSETRON HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include DOLASETRON MESYLATE, GRANISETRON, GRANISETRON HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

22
Approved
5
Phase III
15
Phase II
Assay Mix

Activity Type Distribution

IC50814.0
KI879.0
EC5045.0
KD22.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1189679 10.5 Ki 0.03162 Approved
CHEMBL261010 10.4 Ki 0.04 Preclinical
CHEMBL475331 10.29 Ki 0.05129 Preclinical
CHEMBL1643895 10.22 Ki 0.06 Approved
CHEMBL46 10.05 IC50 0.09 Approved
CHEMBL145033 9.86 Ki 0.138 Preclinical
CHEMBL145725 9.84 Ki 0.1445 Preclinical
CHEMBL596951 9.77 Ki 0.17 Preclinical
CHEMBL28992 9.74 Ki 0.182 Preclinical
CHEMBL3916920 9.74 IC50 0.18 Preclinical
Distribution

pChEMBL Value Distribution

100
5.0
127
5.5
139
6.0
99
6.5
105
7.0
97
7.5
119
8.0
235
8.5
216
9.0
31
9.5
pChEMBL
Approved Drugs

Approved Drugs

RAMOSETRON
CHEMBL1643895
Approved 2015
Properties Compare Identifier
VORTIOXETINE
CHEMBL2104993
Approved 2013
Properties Compare Identifier
PALONOSETRON
CHEMBL1189679
Approved 2003
Properties Compare Identifier
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
Properties Compare Identifier
ALOSETRON
CHEMBL1110
Approved 2000
Properties Compare Identifier
KETOTIFEN FUMARATE
CHEMBL1633
Approved 1999
Properties Compare Identifier
OLANZAPINE
CHEMBL715
Approved 1996
Properties Compare Identifier
GRANISETRON
CHEMBL289469
Approved 1993
Properties Compare Identifier
SUMATRIPTAN
CHEMBL128
Approved 1992
Properties Compare Identifier
ONDANSETRON
CHEMBL46
Approved 1991
Properties Compare Identifier
CLOZAPINE
CHEMBL42
Approved 1989
Properties Compare Identifier
Assay Landscape

Assay Landscape

509
Total Assays
938
Tested Compounds
4
Assay Types
Binding — 466 assays, 938 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 305 270 6.9
cell-based format 116 570 7.8
assay format 44 98 7.3
tissue-based format 1 0 —
Functional — 34 assays, 69 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 25 34 5.6
assay format 9 35 5.6
ADME — 8 assays, 75 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 51 6.5
single protein format 3 24 6.6
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 5.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine